Neuroprotective mechanism of *Kai Xin San*: upregulation of hippocampal insulin-degrading enzyme protein expression and acceleration of amyloid-beta degradation

Na Wang¹, Yong-ming Jia¹, Bo Zhang², Di Xue¹, Maharjan Reeju¹, Yan Li¹, Shu-ming Huang², Xue-wei Liu¹,*

¹ Institute of Medicine, Qiqihar Medical University, Qiqihar, Heilongjiang Province, China
² Department of Neuroscience, Institute of Traditional Chinese Medicine, Heilongjiang University of Chinese Medicine, Harbin, Heilongjiang Province, China


Open access statement: This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as the author is credited and the new creations are licensed under the identical terms.

Abstract

*Kai Xin San* is a Chinese herbal formula composed of *Radix Ginseng, Poria, Radix Polygalae* and *Acorus Tatarinowii Rhizome*. It has been used in China for many years for treating amnesia. *Kai Xin San* ameliorates amyloid-β (Aβ)-induced cognitive dysfunction and is neuroprotective in vivo, but its precise mechanism remains unclear. Expression of insulin-degrading enzyme (IDE), which degrades Aβ, is strongly correlated with cognitive function. Here, we injected rats with exogenous Aβ₄₂ (200 μM, 5 μL) into the hippocampus and subsequently administered *Kai Xin San* (0.54 or 1.08 g/kg/d) intragastrically for 21 consecutive days. Hematoxylin-eosin and Nissl staining revealed that *Kai Xin San* protected neurons against Aβ-induced damage. Furthermore, enzyme-linked immunosorbent assay, western blot and polymerase chain reaction results showed that *Kai Xin San* increased expression of IDE protein, but not mRNA, in the hippocampus. Our findings reveal that *Kai Xin San* facilitates hippocampal Aβ degradation and increases IDE expression, which leads, at least in part, to the alleviation of hippocampal neuron injury in rats.

Key Words: nerve regeneration; neurodegeneration; traditional Chinese medicine; *Kai Xin San*; insulin-degrading enzyme; amyloid-β; Alzheimer's disease; Chinese herbal compound; Aβ-degrading enzymes; neurons; *Radix Ginseng, Radix Polygalae, Acorus Tatarinowii Rhizoma*; neural regeneration

Introduction

Amyloid-β (Aβ), a key biomolecule in senile plaques, plays a central role in the pathology of Alzheimer's disease (AD) (Amici et al., 2016; Chai et al., 2016; Zhang et al., 2016). In the brain, under physiological conditions, Aβ is constantly generated from amyloid precursor protein and cleaved by β- and γ-secretases (Li et al., 2016; Niu et al., 2016). It is widely accepted that abnormal accumulation of Aβ, containing Aβ₄₂ and Aβ₄₀, participates in the pathology of AD (Awasthi et al., 2016; Wang, 2016). Aβ₄₂, which is hydrophobic and prone to aggregation, seems to be more neurotoxic than Aβ₄₀ in AD. It is mostly degraded by Aβ-degrading enzymes, but an imbalance between its generation and degradation leads to pathological Aβ accumulation in AD (Saido, 2013). Howev-
Aβ and KXS administration

200 rats were equally and randomly allocated to four groups: control, model, low-dose KXS (KXSL) and high-dose KXS (KXSH, Table 1). Aβ1-42 (Wako Pure Chemical Industries, Ltd., Japan) was dissolved in dimethyl sulfoxide and diluted with 0.9% saline. For intrahippocampal Aβ1-42 injection (all groups except control), rats were anesthetized with 3% pentobarbital sodium (50 mg/kg) and fixed in a stereotaxic instrument as previously described (Asle-Rousht et al., 2013). Aβ1-42 solution was injected into the hippocampus bilaterally at the following coordinates: 3.6 mm posterior to the bregma, 2.2 mm lateral to the midline and 4.0 mm below the top of the skull. A total of 10 µL per rat (5 µL each side, 200 µM) was injected over 10 minutes. The needle was slowly withdrawn from the brain, the surgical incision was sutured, and penicillin sodium was administered to prevent infection. Control rats underwent the same procedure, but same volume of saline was injected instead of Aβ. Subsequently, rats received KXS (KXSL group, 0.54 g/kg/d; KXSH group, 1.08 g/kg/d) or an equivalent volume of saline (control and model groups) intragastrically once a day for 21 consecutive days. Forty rats were used for histology and Nissl staining (n = 10 per group) and 160 for the enzyme-linked immunosorbent assay (ELISA) (n = 40 per group).

Histological staining

Rats were anesthetized with 10% (3.5 mL) chloral hydrate and decapitated after perfusion with 10% formalin and the brain was removed immediately. Brains from the rats in each group (Table 1) were fixed with 10% formalin for hematoxylin-eosin and Nissl staining. The tissue containing the hippocampus was dehydrated through a graded series of alcohol (75%, 85%, 95%, and 100%), embedded in paraffin, and sliced into 4-µm-thick sections. These sections were deparaffinized and subjected to hematoxylin-eosin and Nissl staining (Ooigawa et al., 2006; Zhou et al., 2012). Under a microscope (Olympus, Tokyo, Japan), a 300 × 100 µm² field of view was selected at random to count the number of injured cells (showing nuclear shrinkage or disappearance) and total cells in the hippocampal dentate gyrus, and the percentage of injured cells was calculated.

ELISA assay for injected Aβ1-42

At five time points after injection (12, 24, 48, 96 and 168 hours; n = 8 rats per time point), brain Aβ1-42 concentration was measured. Rats were anesthetized with 10% (3.5 mL) chloral hydrate and decapitated. The brains were quickly dissected on ice at the allocated time-point. For ELISA, brains were homogenized in 70% formic acid buffer (1:10 w/v) for 1 hour. The lysates were centrifuged at 12,000 g for 30 minutes. The supernatants were collected and neutralized with 1 M Tris-base solution. The solution containing Aβ1-42 was measured using a specific and sensitive sandwich ELISA kit (Wako Pure Chemical Industries, Ltd., Japan). Total protein concentration was measured using the BCA method.

Table 1 Group assignment and drug treatment

<table>
<thead>
<tr>
<th>Experiments</th>
<th>n</th>
<th>Groups</th>
<th>Aβ injection to hippocampus</th>
<th>Orally given KXS (g/kg/d)</th>
<th>Duration for KXS treatment (day)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Histological staining and Nissl staining</td>
<td>40</td>
<td>Control (n = 10)</td>
<td>−</td>
<td>−</td>
<td>21</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Model (n = 10)</td>
<td>+</td>
<td>−</td>
<td>21</td>
</tr>
<tr>
<td></td>
<td></td>
<td>KXSL (n = 10)</td>
<td>+</td>
<td>0.54</td>
<td>21</td>
</tr>
<tr>
<td></td>
<td></td>
<td>KXSH (n = 10)</td>
<td>+</td>
<td>1.08</td>
<td>21</td>
</tr>
<tr>
<td>ELISA for injected Aβ&lt;sub&gt;1-42&lt;/sub&gt;</td>
<td>160</td>
<td>Control (n = 40) ¹</td>
<td>−</td>
<td>−</td>
<td>21</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Model (n = 40) ²</td>
<td>+</td>
<td>−</td>
<td>21</td>
</tr>
<tr>
<td></td>
<td></td>
<td>KXL (n = 40)</td>
<td>+</td>
<td>0.54</td>
<td>21</td>
</tr>
<tr>
<td></td>
<td></td>
<td>KXSH (n = 40)</td>
<td>+</td>
<td>1.08</td>
<td>21</td>
</tr>
<tr>
<td>Western blot assay and real-time PCR</td>
<td>30</td>
<td>Control (n = 10)</td>
<td>−</td>
<td>−</td>
<td>21</td>
</tr>
<tr>
<td></td>
<td></td>
<td>KXSL (n = 10)</td>
<td>−</td>
<td>0.54</td>
<td>21</td>
</tr>
<tr>
<td></td>
<td></td>
<td>KXSH (n = 10)</td>
<td>−</td>
<td>1.08</td>
<td>21</td>
</tr>
</tbody>
</table>

KXS: Kai Xin San; KXSL: low-dose KXS; KXSH: high-dose KXS; Aβ: amyloid-beta; ELISA: enzyme linked immunosorbent assay; PCR: polymerase chain reaction. ¹: n = 8 rats per time point (12, 24, 48, 96, or 168 hours after Aβ<sub>1-42</sub> injection); +: administered; −: not administered.

Table 2 Sequences of primers used for real-time polymerase chain reaction

<table>
<thead>
<tr>
<th>Gene</th>
<th>Sequences (5’-3’)</th>
<th>Product size (bp)</th>
</tr>
</thead>
<tbody>
<tr>
<td>IDE</td>
<td>Forward: AGT TAA AAG AAG CCC TCG ATG</td>
<td>160</td>
</tr>
<tr>
<td></td>
<td>Reverse: TGC TCA ATA AGG GTG TCT TCT AC</td>
<td></td>
</tr>
<tr>
<td>β-Actin</td>
<td>Forward: AGA GGC ATC CTG ACC CTG AAG</td>
<td>163</td>
</tr>
<tr>
<td></td>
<td>Reverse: GGT TGG CCT TAG GGT TCA GAG</td>
<td></td>
</tr>
</tbody>
</table>

IDE: Insulin-degrading enzyme.

Western blot assay

Thirty rats were equally and randomly allocated to three groups (Table 1). Rats were anesthetized with 10% (3.5 mL) chloral hydrate and decapitated. Brains were removed on ice and hippocampi were dissected out for western blot and real-time-polymerase chain reaction (PCR) assays. To measure IDE content, hippocampal tissue was lysed in radioimmunoprecipitation assay buffer containing protease inhibitor. Protein content was determined using the Bradford method. Samples were mixed with an equal volume of 2× loading buffer and proteins were denatured by boiling at 100°C for 5 minutes. Protein samples (2 μg/L) were resolved using sodium dodecyl sulfate polyacrylamide gel electrophoresis with a 10% gel and transferred to polyvinylidene fluoride membranes. Blots were blocked in 5% non-fat milk for 2 hours at room temperature, then incubated with primary polyclonal antibody against human IDE (1:400; Santa Cruz Biotechnology, Santa Cruz, CA, USA) overnight at 4°C. Immunoreactive bands were probed with a horseradish peroxidase-linked secondary polyclonal antibody (1:800; Beyotime Institute of Biotechnology, Haimen, China) for 2 hours. Enhanced chemiluminescence detection (Beyotime Institute of Biotechnology, Shanghai, China) was used to quantify the optical densities of immunoreactive bands. All protein bands were converted to gray values and compared against the internal reference protein (β-actin, Beyotime Institute of Biotechnology, Shanghai, China). Protein expression was quantified using Gel-Pro Analyzer 3.0 software (Media Cybernetics, Inc., Rockville, MD, USA).

Real time-PCR for detecting IDE mRNA

Total hippocampal RNA was extracted using TRIzol Reagent (TaKaRa Biotechnology (Dalian) Co., Ltd., Dalian, China) according to the manufacturer’s protocol. RNA concentration was then measured using ultraviolet spectroscopy. Total RNA was used to prepare cDNA by reverse transcription using a SYBR Premix Ex Taq kit (TaKaRa Biotechnology (Dalian) Co., Ltd.). For detection of IDE mRNA, primers were designed using Primer 5 software (downloaded from https://www.genscript.com/ssl-bin/app/primer) (Table 2). cDNA was amplified using a SYBR Premix Ex Taq kit (TaKaRa Biotechnology (Dalian) Co., Ltd.). The PCR protocol consisted of denaturation at 95°C for 30 seconds followed by 40 denaturation and annealing cycles (95°C for 5 seconds, 60°C for 34 seconds). β-Actin was used as an internal reference. IDE mRNA expression was quantified using the 2<sup>−ΔΔCt</sup> method.

Statistical analysis

All data, expressed as the mean ± SD, were analyzed using SPSS 13.0 software (SPSS, Chicago, IL, USA). One-way analysis of variance was used for comparisons of multiple groups and the least significant difference test was used between two groups. P < 0.05 was considered significant.

Results

Effect of KXS on neuronal injury induced by hippocampal Aβ<sub>1-42</sub> injection

Hematoxylin-eosin and Nissl staining were performed to investigate the neuroprotective effect of KXS. As expected, Aβ<sub>1-42</sub> injection induced hippocampal neuronal injury, which was prevented by KXS. Hematoxylin-eosin staining revealed irregular neurons and neuronal death around the injection site (Figure 1B). However, neuronal injuries were markedly less severe after treatment with KXS (Figure 1C, D), and the number of injured neurons in the KXS group was significantly lower than in the model group (F = 23.5; P = 0.03 and P < 0.005 Figure 1E). Accordingly, Nissl staining also revealed typical neuronal pathological changes, including neuronal loss and nucleus shrinkage or disappearance, in the hippocampal den-
tate gyrus in the model group (Figure 2B), and were reversed significantly after treatment with KXS (Figure 2C, D). The proportion of injured neurons was significantly lower in the KXSL group ($F = 20.6; P = 0.04$) and KXSH group ($P = 0.007$) than in the model group (Figure 2E).

**KXS effect on degradation of Aβ$_{42}$**
We explored why KXS reduces Aβ$_{42}$-induced histological injury. Aβ$_{42}$ levels in all groups declined between 6 and 96 hours, indicating that some Aβ$_{42}$ clearance occurred without treatment. However, at 12, 24, 48, 96 and 168 hours, Aβ$_{42}$ levels were significantly lower in the KXS groups than in the model group, and lower in the KXSH group than in the KXSL group (Figure 3).

**Effect of KXS on IDE mRNA and protein expression**
To further explore the KXS-induced reduction in Aβ$_{42}$ levels, hippocampal IDE protein expression was investigated by western blot assay. Rats in the KXS groups showed significant upregulation of IDE protein after 168 hours compared with the model group ($P < 0.01$). IDE protein expression increased more in the KXSH group than in the KXSL group (Figure 4A). However, no significant difference in IDE mRNA expression was found between the KXS groups and the model group (Figure 4B). These results indicate that KXS accelerated Aβ degradation by upregulating IDE expression in the brain.

**Discussion**
KXS treatment improves the cognitive dysfunction induced by intrahippocampal Aβ injection (Li et al., 2013). Moreover, rat plasma containing KXS alleviated Aβ$_{42}$-induced damage in PC12 cells (Wen et al., 2012). These results tightly link the pharmacological targets of KXS to Aβ$_{42}$. The present study showed that KXS prevented neuronal injury induced by Aβ$_{42}$ and suggested that the therapeutic efficacy of KXS was related to Aβ in treating cognitive dysfunction.

KXS improves learning and memory in several paradigms, including experimental AD (Hu et al., 2013). However, whether KXS can affect Aβ degradation and clearance is not clear. The present results show that Aβ$_{42}$ levels were significantly reduced after treatment with KXS. Because the excessive accumulation of Aβ is regarded as an essential upstream process in the AD pathogenesis cascade, we speculated that KXS might promote Aβ degradation.

Although insulin was long considered the main substrate for IDE, it was recently shown that IDE also degrades Aβ into peptides in the brain (Baranello et al., 2015). In addition, the process of substrate degradation by IDE has been elucidated: a proteolytic chamber, formed by the N and C terminal units of IDE, cleaves only peptides of up to 70 amino acids (Shen et al., 2006). In the brain, IDE is secreted from neurons and microglia, and Aβ degradation takes places extracellularly as well as in the cell membrane (Qiu et al., 1998; Zhang et al., 2013). Some studies reported an association of polymorphisms in the IDE locus with the risk of AD and plasma Aβ levels (Vekrellis et al., 2000; Carrasquillo et al., 2010; Cheng et al., 2015). Most clinical studies confirmed that IDE activity or expression is lower in AD and in individuals at high risk of AD (Perez et al., 2000; Del Campo et al., 2015). Moreover, an increase of cerebral endogenous Aβ was found after IDE inhibition or knockout (Shen et al., 2006). These studies suggest that IDE participates in the degradation of Aβ, and that its dysfunction contributes to the increase of Aβ in the brain. Therefore, in our study, we explored whether KXS would alter IDE expression.

Indeed, there was a significant increase in IDE protein expression after treatment with KXS, suggesting that this is an important reason for the decrease in Aβ$_{42}$. Consistent with this, some active components from KXS have the ability to increase the protein level and activity of IDE. For instance, ginsenoside Rg1, one of the major active ingredients of KXS, can increase IDE expression by upregulating PPARY, leading to lower levels of Aβ$_{42}$ in the hippocampus (Quan et al., 2013). Ginsenosides Rg3 and Rb1, which act on the insulin signal transduction pathway, also can upregulate IDE protein expression, implying that the insulin pathway may be involved in regulating IDE expression (Gu et al., 2014; Jang et al., 2015). Together, these findings suggest that KXS and its active constituents can increase IDE expression. However, according to our PCR results, the mRNA level of IDE did not change. There are a number of possible reasons for these inconsistent changes. One is that rapid transcription coupled with rapid degradation will result in no change in RNA survival and availability for translation, and therefore cannot account for increased protein production. Conversely, KXS may regulate post-transcriptional changes, such as increased translation efficiency or reduced protein degradation, without affecting the mRNA level of IDE (Rodnina, 2016). These complicated molecular mechanisms represent an even greater challenge and should be addressed in subsequent studies.

In summary, the results of the present study demonstrate for the first time that KXS accelerates Aβ degradation by upregulating IDE protein expression and improving cognitive dysfunction. KXS is a promising agent for the treatment of AD.

**Author contributions:** NW designed the study and wrote the paper. YML provided critical revision of the paper for intelligent content. BZ, YL, DY, and MR analyzed data. SMH designed the study. XWL designed the experiment. YMJ provided critical revision of the paper for intellectual content. BZ, YL, DY, and MR analyzed data. SMH designed the study. XWL designed the experiment. YMJ provided critical revision of the paper for intellectual content. BZ, YL, DY, and MR analyzed data. SMH designed the study. XWL designed the experiment. YMJ provided critical revision of the paper for intellectual content.

**Conflicts of interest:** None declared.

**Plagiarism check:** This paper was screened twice using CrossCheck to verify originality before publication.

**Peer review:** This paper was double-blinded and stringently reviewed by international expert reviewers.

**References**


567
Figure 1 Effect of KXS on neuronal injury in the hippocampal dentate gyrus of rats after Aβ42 injection.

(A) Site of Aβ injection (arrows) (∗×10). (B–E) Hematoxylin-eosin staining (∗× 200), showing neuronal injury in hippocampal dentate gyrus of control group (no Aβ or KXS) (B), model group (Aβ without KXS) (C), KXSL group (Aβ + 0.54 g/kg/d KXS, i.g.) (D), and KXSH group (Aβ + 1.08 g/kg/d KXS, i.g.) (E). Red arrows: Injured cells. (F) A 300 × 100 μm² field was selected at random to count the number of injured (nuclear shrinkage or disappearance) and total cells in the area around the Aβ injection site. The proportion of damaged cells was significantly greater in the model group than in the control group, and significantly lower in the KXSH and KXSL groups than in the model group. Data are expressed as the mean ± SD (∗P < 0.05, **P < 0.01; n = 10; one-way analysis of variance followed by the least significant difference post hoc test). KXS: Kai Xin San; KXSL: low-dose KXS; KXSH: high-dose KXS; Aβ: amyloid-beta; d: day.

Figure 2 Hippocampal dentate gyrus histopathology.

(A–D) Representative Nissl stained sections (∗× 200) from animals in the control group (no Aβ or KXS) (A), model group (Aβ without KXS) (B), KXSL group (Aβ + 0.54 g/kg/d KXS, i.g.) (C), and KXSH group (Aβ + 1.08 g/kg/d KXS, i.g.) (D). Model group shows neuronal loss and nuclear shrinkage or disappearance (red arrows). KXSL and KXSH groups show fewer histopathological changes. (E) Quantification of injured cells. There was a significantly higher percentage of damaged cells in the model group than in the control group, and a significantly lower percentage in the KXSH and KXSL groups than in the model group. Data are expressed as the mean ± SD (∗P < 0.05, **P < 0.01; n = 10; one-way analysis of variance followed by the least significant difference post hoc test). KXS: Kai Xin San; KXSL: low-dose KXS; KXSH: high-dose KXS; Aβ: amyloid-beta; d: day.

Figure 3 KXS accelerated the degradation of injected Aβ42.

Aβ level decreased over time in all groups. However, at 12, 24, 48, 96 and 168 hours, Aβ levels in the KXSH group and KXSL group were lower than in the model group. Data are expressed as the mean ± SD (∗P < 0.05, **P < 0.01; n = 10; one-way analysis of variance followed by the least significant difference post hoc test). KXS: Kai Xin San; KXSL: low-dose KXS; KXSH: high-dose KXS; Aβ: amyloid-beta; d: day.


Figure 4 KXS upregulates IDE protein expression but has no effect on IDE mRNA expression.


Yanjiu 20:7307-7313.

